3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
Subscribe To Our Newsletter & Stay Updated
